Qilu Hospital of Shandong University: Stomach Neoplasms trials

The registry lists 16 Stomach Neoplasms studies with Qilu Hospital of Shandong University as lead sponsor. 11 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 6No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric CancerRecruitingNCT07635836Not applicable
• Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric CancerRecruitingNCT07537361Phase 2
• Safety and Efficacy of Leucine-Restricted Diet in Gastric CancerEnrolling by invitationNCT07488312Phase 1
• Early Postoperative Intervention in Gastric Cancer PatientsEnrolling by invitationNCT07444099Not applicable
• Prolonged Extubation in Gastric Cancer With OSAEnrolling by invitationNCT07362706
• Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant AscitesRecruitingNCT06759064Phase 1/2
• First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingNCT06730373Phase 2
• First-Line and Neoadjuvant Immunotherapy for Gastric CancerRecruitingNCT06727981
• Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric CancerNot yet recruitingNCT06421220Not applicable
• The Role of Artificial Intelligence in Endoscopic Diagnosis of Esophagogastric Junctional Adenocarcinoma：A Single Center, Case-control, Diagnostic StudyNot yet recruitingNCT05819099
• Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on MultiomicsRecruitingNCT05812287
• Postoperative Adjuvant Therapy for Stage II-III Gastric CancerActive, not recruitingNCT06609759
• Minimal Residual Disease-guided Adjuvant Therapy for Gastric CancerActive, not recruitingNCT06157216Not applicable
• First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Phase 2
• Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GCStatus unknownNCT05198856Phase 1/2
• Neoadjuvant Immunotherapy for Resectable Gastric CancerCompletedNCT03878472Phase 2